Public Employees Retirement System of Ohio acquired a new stake in shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 37,366 shares of the company’s stock, valued at approximately $1,782,000. Public Employees Retirement System of Ohio owned approximately 0.09% of Pacira Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Ameritas Investment Partners Inc. increased its holdings in shares of Pacira Pharmaceuticals by 9.6% during the second quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock valued at $165,000 after acquiring an additional 302 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Pacira Pharmaceuticals by 6.6% during the second quarter. The Manufacturers Life Insurance Company now owns 30,307 shares of the company’s stock valued at $1,446,000 after acquiring an additional 1,872 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of Pacira Pharmaceuticals during the second quarter valued at about $572,000. Cubist Systematic Strategies LLC increased its holdings in shares of Pacira Pharmaceuticals by 121.5% during the second quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock valued at $152,000 after acquiring an additional 1,752 shares in the last quarter. Finally, BlueCrest Capital Management Ltd acquired a new position in shares of Pacira Pharmaceuticals during the second quarter valued at about $495,000.

Several research firms have recently issued reports on PCRX. Cowen and Company restated a “hold” rating on shares of Pacira Pharmaceuticals in a report on Friday, July 14th. Wedbush restated an “outperform” rating and set a $87.00 price objective on shares of Pacira Pharmaceuticals in a report on Wednesday, July 19th. Mizuho restated a “buy” rating and set a $54.00 price objective on shares of Pacira Pharmaceuticals in a report on Wednesday, July 26th. Canaccord Genuity set a $56.00 price objective on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, July 25th. Finally, BidaskClub downgraded shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $50.43.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/public-employees-retirement-system-of-ohio-acquires-new-holdings-in-pacira-pharmaceuticals-inc-pcrx/1680194.html.

In other news, CAO Kristen Marie Williams sold 3,461 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $36.75, for a total transaction of $127,191.75. Following the sale, the chief accounting officer now owns 21,312 shares of the company’s stock, valued at approximately $783,216. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Paul J. Hastings sold 1,044 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $36.15, for a total transaction of $37,740.60. Following the sale, the director now directly owns 3,518 shares in the company, valued at approximately $127,175.70. The disclosure for this sale can be found here. Insiders have sold a total of 33,390 shares of company stock worth $1,215,480 in the last ninety days. Corporate insiders own 6.60% of the company’s stock.

Shares of Pacira Pharmaceuticals, Inc. (PCRX) opened at $36.10 on Friday. Pacira Pharmaceuticals, Inc. has a one year low of $29.81 and a one year high of $58.95. The company has a current ratio of 7.84, a quick ratio of 7.26 and a debt-to-equity ratio of 1.03.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Wednesday, August 2nd. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.06). The firm had revenue of $70.90 million for the quarter, compared to analyst estimates of $73.37 million. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. Pacira Pharmaceuticals’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.21 EPS. equities analysts forecast that Pacira Pharmaceuticals, Inc. will post -0.96 earnings per share for the current year.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.